Peptides E4 or Ibio100

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

Dune

Age29

Dune

Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based in part upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university.  After careful consideration, we have decided to terminate all efforts on IBIO-100 anti-fibrotic program and to cancel the license agreement with the University of Pittsburgh. The lead optimization and manufacturing of IBIO-100 have proven to be very challenging, and we will continue to prioritize our resources to fit into our immune-oncology monoclonal antibody strategy.


As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program.

31/12/2022
Age29

Sergey070907

so it turns out we can forget about peptid e4?
34 years old,onset of illness at age 22,injury, loss of length and girth, loss of sensitivity, erection preserved.Ultrasound showed thickening of the tunica.Treatment at the onset of the disease: electrophoresis with longidase.No major changes.